The VERIFY trial explores rusfertide to manage polycythemia vera without causing iron deficiency symptoms, Dr. Aaron Gerds explained.

Rusfertide (Protagonist Therapeutics/Takeda Pharmaceuticals) — administered as a once-weekly subcutaneous injection — also ...

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a ...

The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among ...

The novel drug reduces the need for burdensome phlebotomy and also addresses fatigue, thereby improving quality of life for ...

Panelists discuss how ruxolitinib provides comprehensive benefits for polycythemia vera patients beyond count control, highlighting its remarkable ability to rapidly alleviate severe pruritus (often ...

Rusfertide could be a new treatment option for patients with polycythemia vera, according to Andrew Kuykendall, MD.

For patients with a rare type of blood cancer, treatment might finally be coming out of the Dark Ages. People with the ...

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet ...

Dr. Tiziano Barbui explains how excess blood cell production in certain myeloproliferative neoplasms can impair circulation and why treatments like phlebotomy are used.

If you’re a fan of comedies, there’s a good chance you’ve come across the multitalented filmmaker Todd Strauss-Schulson.